2009
DOI: 10.1590/s0004-282x2009000500031
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: -Autism spectrum disorders (ASD) are neurodevelopment disorders that cause severe and pervasive impairment in socialization, communication, and behavior. Although the availability of antipsychotic treatment in ASD has expanded, we will be very careful with side effects of these pharmacological agents. Following this reasoning, emerging data indicate that some antipsychotics may be associated with cardiovascular adverse events (e.g., QT interval prolongation), suggesting that this could be correlated to sudden … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2011
2011
2012
2012

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 45 publications
(51 reference statements)
0
3
0
Order By: Relevance
“…Ray and colleagues found that users of atypical antipsychotic drugs have a similar dose-related increased risk of sudden cardiac death (twice) in comparison with users of typical ones [78]. Several studies confirm that atypical antipsychotic drugs increase the cardiac risk to the same extent as typical antipsychotic drugs [76,82,83,85,87,89,[92][93][94][95][96][97][98]. Indeed, some authors have argued that atypical antipsychotic drugs should be preferred in clinical practice because they do not increase cardiac risk [ Schneider and Lizer demonstrated that paliperidone can cause atrial fibrillation [95], but Riedel and collaborators found that atypical antipsychotics do not cause arrhythmias in elderly patients with schizophrenia [101].…”
Section: Reviewmentioning
confidence: 98%
See 1 more Smart Citation
“…Ray and colleagues found that users of atypical antipsychotic drugs have a similar dose-related increased risk of sudden cardiac death (twice) in comparison with users of typical ones [78]. Several studies confirm that atypical antipsychotic drugs increase the cardiac risk to the same extent as typical antipsychotic drugs [76,82,83,85,87,89,[92][93][94][95][96][97][98]. Indeed, some authors have argued that atypical antipsychotic drugs should be preferred in clinical practice because they do not increase cardiac risk [ Schneider and Lizer demonstrated that paliperidone can cause atrial fibrillation [95], but Riedel and collaborators found that atypical antipsychotics do not cause arrhythmias in elderly patients with schizophrenia [101].…”
Section: Reviewmentioning
confidence: 98%
“…Previous studies have demonstrated that atypical antipsychotics drugs cause QTc prolongation [79,[87][88][89], and therefore, increase the risk of dangerous ventricular fibrillation that often leads to sudden cardiac death, as in the case of some typical antipsychotics belonging to the phenothiazine drug group, such as thioridazine, which was discontinued worldwide in June 2005 owing to its cardiotoxicity.…”
Section: Reviewmentioning
confidence: 99%
“…In antipsychotic treated patients n-3 PUFAs have the potential to improve the lipid pattern and the drug-related arrhythmia risk [41], but also to reduce some psychosis related symptoms [42]. The n-3 PUFA supplementation in HIV patients treated with HAART is associated with a significant improvement in dyslipidemia and biomarkers of systemic inflammation level, without significant change in renal and liver enzymes [43].…”
Section: Effects On Secondary Dyslipidemiasmentioning
confidence: 99%